Evotec (EVT) Q4 2024 earnings summary

Executive summary

• Fiscal year 2024 guidance was met with group revenues of EUR 797 million, a 2% increase year-over-year, and strong Q4 performance, supported by robust growth in Just - Evotec Biologics and effective cost-saving measures, including the Priority Reset program delivering EUR 40 million in annualized savings.

• Strategic review and new strategy sharpened focus on technology leadership, operational excellence, and high-growth segments, with a simplified business model and a streamlined asset portfolio.

• Balance sheet strengthened with liquidity at EUR 397 million at year-end and net debt leverage reduced to 1.9x adjusted EBITDA.

• Just - Evotec Biologics delivered 71% revenue growth to EUR 185.6 million, offsetting softness in Shared R&D due to challenging market conditions.

Financial highlights

• Group revenues grew 2% year-over-year to EUR 797 million; Just - Evotec Biologics revenues up 71% to EUR 185.6 million, while Shared R&D declined 9% to EUR 611.4 million.

• Adjusted EBITDA for 2024 was EUR 22.6 million, with Q4 revenues at EUR 221.2 million and a gross margin of 20.8%.

• Operating cash flow in Q4 was EUR 74.2 million, supported by R&D tax credits and income tax reimbursements; investing cash flow benefited from EUR 70 million in equity stake sales.

• Net debt leverage improved to 1.9x, with all financial covenants complied with.

• One-off costs of EUR 54.9 million recognized, below the initial provision.

Outlook and guidance

• 2025 group revenue is expected to grow 5%-10% to EUR 840 million-EUR 880 million, mainly driven by Just - Evotec Biologics.

• Shared R&D revenues are anticipated to remain at 2024 levels, with upside potential if market conditions improve in H2 2025.

• Group-adjusted EBITDA guidance for 2025 is EUR 30 million-EUR 50 million, with R&D expenditures projected at EUR 40-50 million.

• Additional EUR 50 million in gross cost efficiency targeted between 2025 and 2028; mid-term revenue CAGR targeted at 8-12% and EBITDA margin above 20%.